<!DOCTYPE html>
<!-- saved from url=(0104)https://bmo-capital-markets-qa-ui-equity.galepartners.com/research/019b385f-7259-462a-a6f9-34de634d2bf1/ -->
<html lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><script type="text/javascript" async="" src="./test_best_files/analytics.js"></script><script async="" src="./test_best_files/gtm.js"></script><script>!function(e,t,a,n,r){e[n]=e[n]||[],e[n].push({"gtm.start":(new Date).getTime(),event:"gtm.js"});var s=t.getElementsByTagName("script")[0],g=t.createElement("script");g.async=!0,g.src="https://www.googletagmanager.com/gtm.js?id=GTM-M993LG6",s.parentNode.insertBefore(g,s)}(window,document,0,"dataLayer")</script><title>BMO Capital Markets</title><meta name="description" content="BMO Capital Markets"><meta name="author" content="GALE Partners"><meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=1,user-scalable=0"><link rel="shortcut icon" href="https://bmo-capital-markets-qa-ui-equity.galepartners.com/favicon.ico"><link href="./test_best_files/app.28fb4cdf.css" rel="stylesheet"><script style="display: none;">var tvt = tvt || {}; tvt.captureVariables = function (a){for(var b=new Date,c={},d=Object.keys(a||{}),e=0,
f;f=d[e];e++)if(a.hasOwnProperty(f)&&"undefined"!=typeof a[f])try{var g=[];c[f]=JSON.stringify(a[f],function(a,b){try{if("function"!==typeof b){if("object"===typeof b&&null!==b){if(b instanceof HTMLElement||b instanceof Node||-1!=g.indexOf(b))return;g.push(b)}return b}}catch(N){}})}catch(l){}a=document.createEvent("CustomEvent");a.initCustomEvent("TvtRetrievedVariablesEvent",!0,!0,{variables:c,date:b});window.dispatchEvent(a)};window.setTimeout(function() {tvt.captureVariables({'dataLayer': window['dataLayer']})}, 2000);</script></head><body class=""><noscript>&lt;iframe src="https://www.googletagmanager.com/ns.html?id=GTM-M993LG6" height=0 width=0 style=display:none;visibility:hidden&gt;&lt;/iframe&gt;</noscript><script>!function(){function e(){t.style.opacity="0",setTimeout(function(){var o=document.querySelector("#docs-loading-dimmer");document.body.removeChild(o),document.body.setAttribute("class",""),window.removeEventListener("load",e)},o)}var o=500,t=document.querySelector("#docs-loading-dimmer");t.style.transition="opacity "+o+"ms linear",window.addEventListener("load",e)}()</script><script type="text/javascript" id="" src="./test_best_files/js"></script><main id="app"><div data-reactroot=""><div id="layout-container" class="ui fluid container"><div class="research-layout-builder"><div><div class="ui container header-container"><div class="auth-modal-container"></div><div class="top-header"><div class="header-wrapper"><div class="three wide computer twelve wide mobile twelve wide tablet column bmo-logo"><div class="logo"><a class="active" aria-current="true" href="https://bmo-capital-markets-qa-ui-equity.galepartners.com/"><img class="ui image bmo-header-logo" alt="BMO Equity Logo" src="./test_best_files/FF2FD62C-B025-44DC-B726-D6C9F2FDB29E.png"><div class="ui heading logo-text"><!-- react-text: 15 -->Equity Research<!-- /react-text --></div></a></div></div><div class="top-header-menu-left-link header-menu-left-list"><a target="_blank" class="header-menu-cell" href="https://www.bmocm.com/">Capital Markets</a><a target="_blank" class="header-menu-cell" href="https://economics.bmocapitalmarkets.com/">Economics</a><a target="_blank" class="header-menu-cell" href="https://bmo-capital-markets-qa-ui-corp.galepartners.com/">Corporate Debt</a></div><div class="user-profile-header-links" id="user-profile-header-links"><div class="name-and-date" id="user-profile-header-name-and-date"><span class="name-label" role="button" tabindex="0">analytics</span></div><div class="user-prof-short-cut-icons"><a class="user-profile false" role="button" tabindex="0"><img class="ui image pop-up-element" alt="Profile Icon" src="./test_best_files/834EE4C4-9F69-47F4-8288-F07900AEC82C.png"></a><a class="user-bookmark false" role="button" tabindex="0"><img class="ui image pop-up-element" alt="Bookmark Icon" src="./test_best_files/04EF02C2-B9D4-4657-B50F-1C9F2A416FEA.png"></a></div><!-- react-empty: 28 --></div></div></div><div class="ui grid regular-header-section"><div class="row"><div class="three wide computer twelve wide mobile twelve wide tablet column bmo-logo"><div class="logo"><a class="active" aria-current="true" href="https://bmo-capital-markets-qa-ui-equity.galepartners.com/"><img class="ui image bmo-header-logo" alt="BMO Header Logo" src="./test_best_files/justbmo-blue2x.png"><div class="ui heading logo-text"><!-- react-text: 36 -->Equity Research<!-- /react-text --></div></a></div></div><div class="mega-menu-container"><img class="ui image desktop" alt="Modal Icon" src="./test_best_files/DF258605-B786-4D0C-BD25-4F4EE9367065.png"><img class="ui image mobile" alt="Header Mega Menu Icon" src="./test_best_files/Screen_Shot_2018-02-08_at_10.03.34_AM.png"><button class="ui button menu-name white" tabindex="0"></button></div><div><div class="search-form-container"><div><div class="ui search search-input-text-box "><div class="ui icon input"><button class="ui button bmo-search-icon search-icon"></button><div class="ui input search-input-text"><input value="" class="prompt" placeholder="Quick Search" aria-label="Search input box"></div><button id="auto-sugg-close" class="ui button cloes-auto-suggest bmo-close-btn"></button></div></div></div></div></div><div class="twelve wide mobile column header-menu-list"><a class="regular-header-menu-item " aria-current="false" href="https://bmo-capital-markets-qa-ui-equity.galepartners.com/our-departments/">Our Department</a><a class="regular-header-menu-item " aria-current="false" href="https://bmo-capital-markets-qa-ui-equity.galepartners.com/library/">Library</a><a class="regular-header-menu-item " aria-current="false" href="https://bmo-capital-markets-qa-ui-equity.galepartners.com/strategy/">Strategy</a><a class="regular-header-menu-item " aria-current="false" href="https://bmo-capital-markets-qa-ui-equity.galepartners.com/quantitativetechnical/">Quantitative/ Technical</a><a class="regular-header-menu-item " aria-current="false" href="https://bmo-capital-markets-qa-ui-equity.galepartners.com/q-model/q-model-monthly-overview/overview/">Q-Model</a><a class="regular-header-menu-item " aria-current="false" href="https://bmo-capital-markets-qa-ui-equity.galepartners.com/data-boutique/">Data Boutique</a></div></div></div></div></div><div class="research-layout-builder-main-wrapper"><div class="ui grid research-layout-builder-grid"><div class="nine wide computer twelve wide mobile seven wide tablet column"><div class="display-publish-date">December 11, 2017 | 23:59 ET | 11:59 ET~</div><div class="ui heading research-title">Celgene</div><div class="ui grid company-performance"><div class="two wide computer column ticker">CELG-NSDQ</div><div class="two wide computer column"><div class="header">Rating</div><div>Outperform</div></div><div class="two wide computer column"><div class="header"><!-- react-text: 141 -->Price: <!-- /react-text --><!-- react-text: 142 -->Dec-11<!-- /react-text --></div><div>$108.00</div></div><div class="two wide computer column"><div class="header">Target</div><div>$155.00</div></div><div class="two wide computer column"><div class="header">Total Rtn</div><div></div></div></div><div class="ui grid main-content"><div class="three wide computer twelve wide mobile six wide tablet column"></div><div class="nine wide computer twelve wide mobile six wide tablet column"><h1 class="ui heading"><!-- react-text: 154 -->Live@ASH: Confluence of Data and New Assays Could Make MRD Approvable Soon<!-- /react-text --></h1><div class="richText"><span class="bottomline-header">Bottom Line : </span>Entering ASH, Minimal Residual Disease (MRD) negativity was a key theme to watch given potential implications for accelerating myeloma development timelines (including for CELG's novel CELMoD programs CC-220 and CC-480 and now also bb2121). Following several supportive clinical trial presentations correlating MRD to outcomes (PFS/OS), plus evidence that new assay technologies are improving sensitivity to levels not previously achieved with near 100% predictive potential, we are inclined to agree with Celgene management, who indicated at their analyst event that approvability on MRD negativity should be "coming soon."</div><h3 class="ui heading"><!-- react-text: 157 -->Key Points<!-- /react-text --></h3><div class="richText"><p><strong>MRD negativity clearly correlates with progression and survival outcomes across multiple myeloma settings.</strong> MRD negativity has been shown to correlate with outcome post ASCT (Myeloma VII, Myeloma IX, Myeloma XI trials), in transplant-ineligible patients (Myeloma XI), in salvage ASCT/relapse (MUK5, Myeloma X), and in deferred ASCT (PADIMAC). This year at ASH, data from the Phase 3 PETHEMA/GEM2012 trial in NDMM, the largest myeloma study to date to embed MRD assessment (N=1,143), showed significant correlation between MRD and PFS. The correlation was progressively better as MRD decreased to 10-6 (i.e., sensitivity level only achievable with Next Gen technologies).</p><p><strong>Recent advancements in assay technology (e.g., Next Gen Flow) should be enough to tip the balance at FDA.</strong> Flow cytometry-based MRD detection methods (initially &lt; 8-color methods with 10-4 limit of detection) were first utilized in clinical trials in the early 2000s and were established prognostic factors by 2007-2010. Second-generation flow (&gt; 8-color, LOD 10-5) enabled prediction of CR and use as a secondary clinical endpoint in the subsequent years. "Next Gen" Flow data at ASH 2017 (10-color, LOD 10-6) has improved predictability of PFS to nearly 100% (still not perfect, longitudinal assessment needed to assure no false positives), which may be enough to justify MRD as a surrogate endpoint (with outcomes as confirmatory analyses), so much so that one presenter (abstract #905) suggested it is the "most relevant clinical endpoint."</p><p><strong>Implications for development timelines.</strong> If the FDA endorses MRD as a surrogate endpoint soon, the biggest impact would be to development timelines for CELMoDs CC-220, CC480 (third-gen molecule potentially an order of magnitude more potent and active in Rev/Pom resistant myeloma) both of which are upside to our model, and bb2121 as well based on plans to collect substantial MRD data in the pivotal trial.</p></div></div></div></div><div class="three wide computer twelve wide mobile five wide tablet column"><div class="ui heading sector-name">Biotechnology</div><div class="analysts-card"><div class="ui grid"><div class="twelve wide computer column"><div class="firstItem"><span class="name">M. Ian Somaiya</span><span class="role">Analyst</span></div><div class="breakWord">ian.somaiya@bmo.com</div><div class="breakWord">(212) 885-4038</div></div></div><div class="ui grid"><div class="twelve wide computer column"><div class=""><span class="name">Steven J Seedhouse</span><span class="role">Associate</span></div><div class="breakWord">steven.seedhouse@bmo.com</div><div class="breakWord">(212) 885-4069</div></div></div><div class="richText text-center"><p class="legalEntity">BMO Capital Markets Corp.</p></div></div><img class="ui image volume-chart" src="./test_best_files/CELG-NSDQ_02_21_2018.cs1.png"><div class="company-data"><table class="ui celled striped table research-layout-table"><thead class=""><tr class="headerRow"><th colspan="3" class="">Company Data</th><th colspan="1" class="">in $</th></tr></thead><tbody class=""><tr class=""><td class="">Dividend</td><td class="">$0.00</td><td class="">Yield</td><td class="">0.0%</td></tr><tr class=""><td class="">Shares O/S (mm)</td><td class="">787.3</td><td class="">Market Cap (mm)</td><td class="">$85,030</td></tr><tr class=""><td class="">AD Vol. (mm)</td><td class="">8.06</td></tr></tbody></table></div><div class="company-data"><table class="ui celled striped table research-layout-table"><thead class=""><tr class="headerRow"><th colspan="3" class="">BMO Estimates</th><th colspan="1" class="">in C$</th></tr><tr class=""><th class="">(FY-Dec)</th><th class="">2016A</th><th class="">2017E</th><th class="">2018E</th></tr></thead><tbody class=""><tr class=""><td class=""><span>EPS</span></td><td class=""><span>$5.94</span></td><td class=""><span>$7.33</span></td><td class=""><span>$8.98</span></td></tr><tr class=""><td class=""><span>MCR</span></td><td class=""><span>-</span></td><td class=""><span>-</span></td><td class=""><span>-</span></td></tr><tr class=""><td class=""><span>OCR</span></td><td class=""><span>-</span></td><td class=""><span>-</span></td><td class=""><span>-</span></td></tr><tr class=""><td class=""><span>Revenue</span></td><td class=""><span>$11,229</span></td><td class=""><span>$12,911</span></td><td class=""><span>$15,101</span></td></tr><tr class=""><td class=""><span>Net Margin</span></td><td class=""><span>-</span></td><td class=""><span>-</span></td><td class=""><span>-</span></td></tr></tbody></table></div><div class="company-data"><table class="ui celled striped table research-layout-table"><thead class=""><tr class="headerRow"><th colspan="3" class="">Consensus Estimates</th><th colspan="1" class="">in C$</th></tr><tr class=""><th class=""></th><th class="">2016A</th><th class="">2017E</th><th class="">2018E</th></tr></thead><tbody class=""><tr class=""><td class=""><span>EPS</span></td><td class=""><span>-</span></td><td class=""><span>$7.34</span></td><td class=""><span>$8.72</span></td></tr></tbody></table></div><div class="company-data"><table class="ui celled striped table research-layout-table"><thead class=""><tr class="headerRow"><th colspan="3" class="">Valuation</th><th colspan="1" class="">in C$</th></tr><tr class=""><th class=""></th><th class="">2016A</th><th class="">2017E</th><th class="">2018E</th></tr></thead><tbody class=""><tr class=""><td class=""><span>P/E</span></td><td class=""><span>18.2x</span></td><td class=""><span>14.7x</span></td><td class=""><span>12.0x</span></td></tr></tbody></table></div><div class="ui warning message"><div class="content"><div class="header">Component work in Progress</div><p>We are working hard at building QtrEPS component</p></div></div></div></div></div><div><div class="footer-wrapper"><div class="ui grid footer"><div class="row footer-grid-row"><div class="eight wide computer twelve wide mobile column footer-links"><div class="ui grid footer-link-section"><div class="row"><div class="three wide computer twelve wide mobile three wide tablet column footer-link-column"><div class="ui heading footer-link-section-title"><!-- react-text: 68 -->Legal<!-- /react-text --></div><div class="footer-link-section-title-mobile false"><div class="ui heading links-title"><!-- react-text: 71 -->Legal<!-- /react-text --><i aria-hidden="true" class="bmo_chevron bottom"></i><!-- react-text: 73 --> <!-- /react-text --></div></div><div class="links-set false"><div class="footer-links-set"><a class="footer-link" aria-current="false" href="https://bmo-capital-markets-qa-ui-equity.galepartners.com/disclosure-statements/">Disclosure Statements</a></div><div class="footer-links-set"><a class="footer-link" aria-current="false" href="https://bmo-capital-markets-qa-ui-equity.galepartners.com/conflict-statements/">Conflict Statements</a></div></div></div><div class="three wide computer twelve wide mobile three wide tablet column footer-link-column"><div class="ui heading footer-link-section-title"><!-- react-text: 81 -->Client<!-- /react-text --></div><div class="footer-link-section-title-mobile false"><div class="ui heading links-title"><!-- react-text: 84 -->Client<!-- /react-text --><i aria-hidden="true" class="bmo_chevron bottom"></i><!-- react-text: 86 --> <!-- /react-text --></div></div><div class="links-set false"><div class="footer-links-set"><a class="footer-link" aria-current="false" href="https://bmo-capital-markets-qa-ui-equity.galepartners.com/library/">Consumption</a></div><div class="footer-links-set"><a class="footer-link" aria-current="false" href="https://bmo-capital-markets-qa-ui-equity.galepartners.com/library/">Profile</a></div><div class="footer-links-set"><a class="footer-link" aria-current="false" href="https://bmo-capital-markets-qa-ui-equity.galepartners.com/library/">Email Preferences</a></div></div></div><div class="three wide computer twelve wide mobile three wide tablet column footer-link-column"><div class="ui heading footer-link-section-title"><!-- react-text: 96 -->BMO<!-- /react-text --></div><div class="footer-link-section-title-mobile false"><div class="ui heading links-title"><!-- react-text: 99 -->BMO<!-- /react-text --><i aria-hidden="true" class="bmo_chevron bottom"></i><!-- react-text: 101 --> <!-- /react-text --></div></div><div class="links-set false"><div class="footer-links-set"><a href="https://www.bmocm.com/" target="_blank" class="footer-link">Capital Markets</a></div><div class="footer-links-set"><a href="https://economics.bmocapitalmarkets.com/" target="_blank" class="footer-link">Economics</a></div><div class="footer-links-set"><a href="https://bmo-capital-markets-qa-ui-corp.galepartners.com/" target="_blank" class="footer-link">Corporate Debt</a></div></div></div><div class="three wide computer twelve wide mobile three wide tablet column footer-address-section"><div class="contact-us-logo"><img class="ui image" alt="Contact Icon" src="./test_best_files/5B4B2233-8E88-4C25-9755-A0B5BF2C5903.png"></div><div class="contact-us-detail"><div class="ui heading footer-link-section-title"><!-- react-text: 114 -->Contact<!-- /react-text --></div><div class="footer-link-section-title-mobile"><div class="ui heading links-title"><!-- react-text: 117 -->Contact<!-- /react-text --><i aria-hidden="true" class="bmo_chevron bottom"></i><!-- react-text: 119 --> <!-- /react-text --></div></div><div class="links-set false"><div class="richText"><div class="rich-text"><h5>Let us contact you</h5><p>A representative will contact 
you at your convenience.<br></p></div></div></div></div></div></div></div></div><div class="three wide computer twelve wide mobile twelve wide tablet column bmo-logo"><div class="logo"><a class="active" aria-current="true" href="https://bmo-capital-markets-qa-ui-equity.galepartners.com/"><img class="ui image bmo-header-logo" alt="BMO  Footer Logo" src="./test_best_files/6E389459-F728-4FFB-9A9D-CE3948D175ED.png"><div class="ui heading logo-text"><!-- react-text: 127 -->BMO Logo<!-- /react-text --></div></a></div></div></div></div></div></div></div></div></div></main><script>document.write("<script type='text/javascript' src='https://bmo-capital-markets-qa-ui-equity.galepartners.com/cms-data-equity.js?v="+Date.now()+"'><\/script>")</script><script type="text/javascript" src="./test_best_files/cms-data-equity.js"></script>
<script type="text/javascript" id="">window.dataLayer=window.dataLayer||[];function gtag(){dataLayer.push(arguments)}gtag("js",new Date);gtag("config","UA-107871429-2");var serverCallCount=1,analyticsEventArray=[];if("undefined"==typeof analyticsEventInterval)var analyticsEventInterval=fireEvents(60);
function fireEvents(a){var b=setInterval(function(){analyticsEventArray.length&&(gtag("event","interact",analyticsEventArray[0]),analyticsEventArray.splice(0,1),serverCallCount++,20===serverCallCount&&(clearInterval(b),fireEvents(500)))},a)};</script>
<script src="./test_best_files/vendor.eb630df6caecb1eb94a3.js"></script><script src="./test_best_files/app.eb630df6caecb1eb94a3.js"></script><script type="text/javascript" id="">(function(a){analyticsEventArray.push({event_category:a.c,event_action:a.a,event_label:a.l,value:a.v,non_interaction:a.n})})(dataLayer[dataLayer.length-1]);</script><script type="text/javascript" id="">(function(a){analyticsEventArray.push({event_category:a.c,event_action:a.a,event_label:a.l,value:a.v,non_interaction:a.n})})(dataLayer[dataLayer.length-1]);</script><script type="text/javascript" id="">(function(a){analyticsEventArray.push({event_category:a.c,event_action:a.a,event_label:a.l,value:a.v,non_interaction:a.n})})(dataLayer[dataLayer.length-1]);</script></body></html>